This page provides the information about the CRC scheme in a nutshell. It is as concise as it can be.
The scheme is focused on external quality assessment of testing of mutations of clinically most important genes
relevant to anti-EGFR therapy in colorectal carcinoma - KRAS, NRAS, BRAF. Participants are expected to identify and describe
mutations, they can choose any combination of KRAS, NRAS, BRAF testing.
For details, please click here and read the page 30 of the EQA Plan 2020.
European Society of Pathology Quality Assurance Foundation
Barastraat 6, 1070 Brussels, Belgium
SEKK s.r.o., Divize EHK
Za Pasáží 1609, 530 02 Pardubice, Czech Republic
Accreditation information: please click here
To view the most current documents (EQA round CRC1/20) please click here.
|Public part of the evaluation|
(EQA round CRC1/20)
|Private part of the evaluation|
(anonymised examples from EQA round CRC1/20)
Confirmation of attendance
|Certificate of approval||Result sheet|
The laboratories from all countries are welcome to participate in CRC scheme.
The document EQA Plan 2021 will be available in October 2020, there will be organised 2 EQA rounds (CRC1/21 in the spring and CRC2/21 in the autumn 2021).
If you aim to participate and/or receive ongoing information you can choose one of the following options:
The registration is free and does not force you to participate and you don't have to worry about annoying emails.
You will be informed about the final EQA Plan 2021 and based on this document you can decide whether to participate in 2021.
Last update: 2.9.2020